1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
44.79%
Cash & equivalents growing 44.79% while Drug Manufacturers - Specialty & Generic shows decline of -5.02%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
No Data
No Data available this quarter, please select a different quarter.
44.79%
Below half the Drug Manufacturers - Specialty & Generic median of -3.98% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
-13.91%
Receivables growth is below half the Drug Manufacturers - Specialty & Generic median of 4.31% (much lower). Joel Greenblatt would investigate if this reflects stronger collection discipline.
-0.89%
Inventory growth less than half of Drug Manufacturers - Specialty & Generic median of 1.74%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
-71.46%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
7.58%
Below half the Drug Manufacturers - Specialty & Generic median of -0.28%. Jim Chanos would question if the company faces working capital strain.
0.28%
PP&E growth below half of Drug Manufacturers - Specialty & Generic median of -0.78%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
1.03%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-0.59%
Near the Drug Manufacturers - Specialty & Generic median of -0.72%. Charlie Munger would see standard intangible growth relative to sector norms.
0.26%
Below half of Drug Manufacturers - Specialty & Generic median of -0.55%. Joel Greenblatt sees relatively minimal intangible expansions vs. peers.
-47.25%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
No Data
No Data available this quarter, please select a different quarter.
1.90%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-0.22%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -0.01%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
1.70%
Below half the Drug Manufacturers - Specialty & Generic median of -0.11%. Jim Chanos might see potential stagnation or distress vs. peers.
-27.13%
Payables growth below half of Drug Manufacturers - Specialty & Generic median of 3.82%. Joel Greenblatt sees more conservative payables management vs. peers.
29.17%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
30.61%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
100.00%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
184.86%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-24.53%
Below half Drug Manufacturers - Specialty & Generic median of 1.07%. Joel Greenblatt sees more conservative short-term leverage than peers.
81.55%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
0.18%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
5979768100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
82.43%
Below half Drug Manufacturers - Specialty & Generic median of -0.92%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects hidden or rapidly growing miscellaneous liabilities.
46.15%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.39%. Jim Chanos suspects an alarming rise in overall leverage.
1.94%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-181.12%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -1.90%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-2820.31%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
-2783.72%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-18.80%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects slower net worth growth or losses vs. peers.
1.70%
Below half Drug Manufacturers - Specialty & Generic median of -0.11%. Jim Chanos suspects a major slowdown or distress.
-47.25%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
72.83%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
87.50%
Above 1.5x Drug Manufacturers - Specialty & Generic median 9.07%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
